Thorac Cardiovasc Surg 2020; 68(03): 223-231
DOI: 10.1055/s-0039-1687843
Original Cardiovascular
Georg Thieme Verlag KG Stuttgart · New York

Microplegia versus Cardioplexol® in Coronary Artery Bypass Surgery with Minimal Extracorporeal Circulation: Comparison of Two Cardioplegia Concepts

Luca Koechlin
1   Department of Cardiac Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
,
Bejtush Rrahmani
1   Department of Cardiac Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
,
Brigitta Gahl
1   Department of Cardiac Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
,
Denis Berdajs
1   Department of Cardiac Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
,
Martin T.R. Grapow
1   Department of Cardiac Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
,
Friedrich S. Eckstein
1   Department of Cardiac Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
,
Oliver Reuthebuch
1   Department of Cardiac Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
› Institutsangaben
Funding We have received no funding for this study.
Weitere Informationen

Publikationsverlauf

22. November 2018

13. März 2019

Publikationsdatum:
25. April 2019 (online)

Abstract

Background The aim of this study is to compare the combined use of the Myocardial Protection System and our microplegia (Basel Microplegia Protocol) with Cardioplexol® in coronary artery bypass grafting using the minimal extracorporeal circulation.

Methods The analysis focused on propensity score matched pairs of patients in whom microplegia or Cardioplexol® was used. Primary efficacy endpoints were high-sensitivity cardiac troponin-T on postoperative day 1 and peak values during hospitalization. Furthermore, we assessed creatine kinase and creatinine kinase-myocardial type, as well as safety endpoints.

Results A total of 56 patients who received microplegia and 155 patients who received Cardioplexol® were included. The use of the microplegia was associated with significantly lower geometric mean (confidence interval) peak values of high-sensitivity cardiac troponin-T (233 ng/L [194–280 ng/L] vs. 362 ng/L [315–416 ng/L]; p = 0.001), creatinine kinase (539 U/L [458–633 U/L] vs. 719 U/L [645–801 U/L]; p = 0.011), and creatinine kinase-myocardial type (13.8 µg/L [9.6–19.9 µg/L] vs. 21.6 µg/L [18.9–24.6 µg/L]; p = 0.026), and a shorter length of stay on the intensive care unit (1.5 days [1.2–1.8 days] vs. 1.9 days [1.7–2.1 days]; p = 0.011). Major adverse cardiac and cerebrovascular events occurred with roughly equal frequency (1.8 vs. 5.2%; p = 0.331).

Conclusions The use of the Basel Microplegia Protocol was associated with lower peak values of high-sensitivity cardiac troponin-T, creatinine kinase, and creatinine kinase-myocardial type and with a shorter length of stay on the intensive care unit, as compared with the use of Cardioplexol® in isolated coronary artery bypass surgery using minimal extracorporeal circulation.

Authors' Contributions

Author L.K.: study design, collection of data, data analysis/interpretation, and writing the manuscript; author B.R.: data collection and critical revision of the manuscript; author B.G.: study design, data collection, data analysis/interpretation, writing the manuscript, and critical revision of the manuscript; author DB: critical revision of the manuscript and operating surgeon; author MG: critical revision of the manuscript and operating surgeon; author FE: critical revision of manuscript and operating surgeon; author OR: study design, data analysis/interpretation, writing manuscript, critical revision of the manuscript, and operating surgeon.


Supplementary Material

 
  • References

  • 1 Cohen DJ, Osnabrugge RL, Magnuson EA. , et al; SYNTAX Trial Investigators. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2014; 130 (14) 1146-1157
  • 2 Farkouh ME, Domanski M, Dangas GD. , et al; FREEDOM Follow-On Study Investigators. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM follow-on study. J Am Coll Cardiol 2019; 73 (06) 629-638
  • 3 Sousa-Uva Miguel, Neumann Franz-Josef, Ahlsson Anders, Alfonso Fernando, Banning Adrian P, Benedetto Umberto. , et al. ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-Thoracic Surgery 2019; 55 (01) 4-90 , https://doi.org/10.1093/ejcts/ezy289
  • 4 Anastasiadis K, Murkin J, Antonitsis P. , et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies International Society (MiECTiS). Interact Cardiovasc Thorac Surg 2016; 22 (05) 647-662
  • 5 Puehler T, Haneya A, Philipp A. , et al. Minimal extracorporeal circulation: an alternative for on-pump and off-pump coronary revascularization. Ann Thorac Surg 2009; 87 (03) 766-772
  • 6 Winkler B, Heinisch PP, Zuk G. , et al. Minimally invasive extracorporeal circulation: Excellent outcome and life expectancy after coronary artery bypass grafting surgery. Swiss Med Wkly 2017; 147: w14474
  • 7 Philipp A, Schmid FX, Foltan M. , et al. Miniaturisierte extrakorporale kreislaufsysteme: Erfahrungsbericht aus über 1000 anwendungen. Kardiotechnik 2006; 15 (01) 3-8
  • 8 van Boven WJ, Gerritsen WB, Waanders FG, Haas FJ, Aarts LP. Mini extracorporeal circuit for coronary artery bypass grafting: initial clinical and biochemical results: a comparison with conventional and off-pump coronary artery bypass grafts concerning global oxidative stress and alveolar function. Perfusion 2004; 19 (04) 239-246
  • 9 Panday GFV, Fischer S, Bauer A. , et al. Minimal extracorporeal circulation and off-pump compared to conventional cardiopulmonary bypass in coronary surgery. Interact Cardiovasc Thorac Surg 2009; 9 (05) 832-836
  • 10 Reuthebuch O, Koechlin L, Gahl B. , et al. Off-pump compared to minimal extracorporeal circulation surgery in coronary artery bypass grafting. Swiss Med Wkly 2014; 144: w13978
  • 11 Pagano D, Milojevic M, Meesters MI. , et al. EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery: the task force on patient blood management for adult cardiac surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiot. Eur J Cardiothorac Surg 2017; 53 (2018): 79-111
  • 12 Kairet K, Deen J, Vernieuwe L, de Bruyn A, Kalantary S, Rodrigus I. Cardioplexol®, a new cardioplegic solution for elective CABG. J Cardiothorac Surg 2013; 8 (Suppl. 01) P120
  • 13 Matt P, Arbeleaz E, Schwirtz G, Doebele T, Eckstein F. Low-Volume, Single-Shot Crystalloid Cardioplegia is Safe for Isolated Aortic Valve Replacement. Thorac Cardiovasc Surg 2012; 60 (05) 360-362
  • 14 Tschopp S, Eckstein F, Matt P. Low-volume cardioplegia and myocardial protection in coronary artery bypass graft surgery. Thorac Cardiovasc Surg 2018 ; (e-pub ahead of print) doi:10.1055/s-0038-1667322
  • 15 Koechlin L, Zenklusen U, Doebele T. , et al. Clinical implementation of a novel myocardial protection pathway in coronary artery bypass surgery with minimal extracorporeal circulation. Perfusion 2018 ; (e-pub ahead of print) doi:10.1177/0267659118815287
  • 16 Gerdisch MW, Robinson S, David G, Makepeace S, Ryan MP, Gunnarsson C. Clinical and economic benefits of advanced microplegia delivery system in cardiac surgery: evidence from 250 hospitals. J Comp Eff Res 2018; 7 (07) 673-683
  • 17 Algarni KD, Weisel RD, Caldarone CA, Maganti M, Tsang K, Yau TM. Microplegia during coronary artery bypass grafting was associated with less low cardiac output syndrome: a propensity-matched comparison. Ann Thorac Surg 2013; 95 (05) 1532-1538
  • 18 Matt P, Arbeleaz E, Schwirtz G, Doebele T, Eckstein F. Low-volume, single-shot crystalloid cardioplegia is safe for isolated aortic valve replacement. Thorac Cardiovasc Surg 2012; 60 (05) 360-362
  • 19 Kuhn EW, Liakopoulos O, Slottosch I. , et al. Buckberg versus Calafiore cardioplegia in patients with acute coronary syndromes. Thorac Cardiovasc Surg 2018; 66 (06) 457-463
  • 20 Gahl B, Göber V, Odutayo A. , et al. Prognostic value of early postoperative troponin T in patients undergoing coronary artery bypass grafting. J Am Heart Assoc 2018; 7 (05) e007743
  • 21 Mauermann E, Bolliger D, Fassl J. , et al. Association of troponin trends and cardiac morbidity and mortality after on-pump cardiac surgery. Ann Thorac Surg 2017; 104 (04) 1289-1297
  • 22 Mauermann E, Bolliger D, Fassl J. , et al. Postoperative high-sensitivity troponin and its association with 30-day and 12-month, all-cause mortality in patients undergoing on-pump cardiac surgery. Anesth Analg 2017; 125 (04) 1110-1117
  • 23 de Lemos JA, Drazner MH, Omland T. , et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304 (22) 2503-2512
  • 24 McQueen MJ, Kavsak PA, Xu L, Shestakovska O, Yusuf S. Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. Clin Biochem 2013; 46 (1,2): 5-9
  • 25 Devereaux PJ, Biccard BM, Sigamani A. , et al; Writing Committee for the VISION Study Investigators. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2017; 317 (16) 1642-1651
  • 26 Everett BM, Brooks MM, Vlachos HEA, Chaitman BR, Frye RL, Bhatt DL. ; BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015; 373 (07) 610-620